A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder
Phase of Trial: Phase III
Latest Information Update: 09 Nov 2017
At a glance
- Drugs Rapastinel (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Acronyms RAP-MD-03
- Sponsors Allergan
- 03 Feb 2017 Planned number of patients changed from 1556 to 700.
- 14 Dec 2016 Planned number of patients changed from 700 to 1556.
- 14 Dec 2016 Planned End Date changed from 1 Nov 2018 to 1 Dec 2018.